SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLASs Phase 3 REGAL trial is the dominant focus, with traders awaiting confirmation of the 80th death that triggers final analysis; the last disclosed count was 78, and speculation links the prolonged wait and company silence to possible ASH disclosures. Bulls interpret the delay as a potential sign of longer survival, while bears question the trial timeline and warn that the outcome remains uncertain; the debate accompanies a sharp share-price decline.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius is being swept into a sharp selloff across AI neocloud and data-center stocks as investors reassess the sectors debt-funded growth, financing costs, and ability to earn returns on heavy infrastructure spending. Traders are split between viewing the decline as an oversold, sector-wide repricing and warning that debt and profitability risks could drive further losses.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

A sharp futures rebound after a bruising week, ahead of major tech earnings, has put SPY in focus amid chatter about the 1987 Black Monday anniversary. Traders are split on whether the move signals a durable recovery or a short-covering bounce that could fade at the open.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovances ESMO data are driving discussion, particularly mature frontline melanoma results for lifileucel plus pembrolizumab showing durable responses and a median progression-free survival of 19.8 months, alongside preliminary sarcoma results. Many traders view the data as supportive of expansion potential, while others stress the small study sizes and say the abstracts largely confirm earlier findings; some attribute the share-price weakness to broader biotech selling rather than a company-specific setback.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Concern over IPO lockup expirations and the potential for insider-share selling is a recurring focus as CBRS faces a steep decline. Traders also point to weakness across AI and semiconductor stocks and question the companys high valuation, growth prospects, and reliance on OpenAI; others argue the selloff is overdone and are buying the dip.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

A sharp futures rebound after a bruising tech selloff is driving QQQ discussion, alongside fears tied to the Black Monday anniversary. Traders are split on whether the bounce marks a durable recovery ahead of major tech earnings or a short-covering rally that could fade, with AI-sector concerns still weighing on sentiment.

Cipher Digital, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Digital Inc.

Ciphers convertible-note offering has intensified concerns about dilution and financing risk, amid a broader selloff in AI data-center and mining stocks as investors reassess debt costs and sector prospects. Traders are divided between bearish concerns about management, leverage and continued declines and bullish hopes that the pullback is overdone given long-term AI infrastructure demand.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: QNX, Secure Communications, and Licensing. The QNX segment includes development of safe and reliable software for embedded systems across technology-driven industries. The Secure Communications segment delivers operational resiliency with a government-grade portfolio of secure, certified solutions for mobile fortification, critical communications and crisis management. The Licensing segment focuses on management and monetization of the firm's global patent portfolio. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is drawing attention for QNX momentum, especially the first Alloy Kore vehicle-platform design win and hopes for more automotive and physical-AI adoption; traders also cite a recent earnings beat and raised outlook. Bullish investors see the deals and backlog as evidence of future growth, while skeptics question how quickly design wins will translate into revenue and whether the share price reflects that potential.

iShares Trust - iShares Semiconductor ETF

iShares Semiconductor ETF

SOXX is drawing attention amid a sharp, extended semiconductor selloff, with traders questioning whether heavy AI infrastructure spending can deliver sufficient returns and citing inflation, rates, and competitive pressures as additional headwinds. The community is split between expecting an oversold bounce and warning that the pullback could deepen into a broader correction.

SPDR Series Trust - State Street SPDR S&P Biotech ETF

SPDR S&P Biotech ETF

XBI is drawing attention amid a broad biotech selloff that traders link to rising yields, rate concerns, and rotation away from riskier small-cap names toward AI and other sectors. The community is split between viewing the decline as an oversold buying opportunity and warning that technical weakness and macro pressure could drive further losses.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Full Transcript: Valneva Q2 2026 Earnings Call

Valneva (NASDAQ:VALN) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below.
This content is powered by Benzinga APIs. For comprehensive financial data andread more...

VALN Stock Plunges 7% After-Hours As UK Revokes Valneva’s IXCHIQ Authorization In Latest Market Setback

Equity

Valneva said the Medicines and Healthcare products Regulatory Agency withdrew the U.K. authorization for IXCHIQ on Wednesday. 


12 Health Care Stocks Moving In Wednesday's After-Market Session

Gainers

Valneva (NASDAQ:VALN) shares rose 20.6% to $7.09 during Wednesday's after-market session. The company's market cap stands at $555.6 million.
Profound Medical (NASDAQ:PROF) stock rose 16.98% to $6.64.read more...

Why Did VALN Stock Surge 24% Today?

The European Medicines Agency validated the marketing authorization application for Valneva’s Lyme disease vaccine, which it developed with Pfizer


Pfizer and Valnevas Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency

Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for PF-07307405, the companies 6-valent outer surface protein A (OspA)-based Lyme disease vaccine candidate...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN...

Valneva (NASDAQ:VALN) Downgraded by Wall Street Zen to Strong Sell

Wall Street Zen lowered shares of Valneva to a "strong sell" rating in a research report on Saturday...

Valneva (NASDAQ:VALN) Sets New 12-Month Low After Analyst Downgrade

Valneva (NASDAQ:VALN) Reaches New 12-Month Low Following Analyst Downgrade...

Valneva SE Sponsored ADR (NASDAQ:VALN) Given Average Recommendation of "Hold" by Analysts

Shares of Valneva SE Sponsored ADR (NASDAQ:VALN - Get Free Report) have been assigned a consensus recommendation of "Hold" from the five brokerages that are currently covering the company, MarketBeat...

Valneva (NASDAQ:VALN) Cut to "Sell" at The Goldman Sachs Group

The Goldman Sachs Group lowered Valneva from a "neutral" rating to a "sell" rating and set a $4.90 price target on the stock. in a report on Wednesday...

Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. It currently provides three proprietary travel vaccines: IXIARO, DUKORAL, and IXCHIQ. The IXIARO is an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis in adults, adolescents, children, and infants aged two months and older. The DUKORAL is a drinkable vaccine that helps prevent diarrhea caused by heat-labile toxin-producing ETEC, as well as cholera. The IXCHIQ is a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus. The company also offers additional vaccines, including VLA1553, VLA15, VLA160, VLA200, VLA1601 and others. Valneva was founded on May 28, 2013 and is headquartered in Saint-Herblain, France.

Valneva SE - ADR

Bullish Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$5.61
Prev Close	$5.91
Open	$5.87
Dividend Yield	0.00%
50-Day Moving Average	$6.32
Beta	0.84
Avg. Volume	30,564.53
PE Ratio	-2.68

52-Week High	$12.18
52-Week Low	$4.75
Market Capitalization	$531.96M
EPS (Annual)	-$1.55
Price to Book	5.74
Revenue Per Employee	$292,457.41

Feed

News

Sentiment

Earnings

Fundamentals

Info

VALN Fundamentals